Imagenetix Announces Formation of Scientific and Medical Advisory Board.

SAN DIEGO -- Imagenetix, Inc. (OTCBB:IAGX), www.imagenetix.net, an innovator of scientifically tested, natural-based, proprietary bioceutical products that enhance human health, announced today the formation of a Scientific and Medical Advisory Board that will lend guidance to the company's research and provide counsel related to product development.

Formation of the Advisory Board follows a March 2005 gathering in San Diego, of both medical and scientific professionals, hosted by Imagenetix, and overseen by Dr. Robert Hesslink Jr., Director of Research and Development for Imagenetix. Among other relevant issues, discussions centered around Imagenetix's previous published studies and the on-going research of Celadrin(R), www.celadrin.com, a proprietary Imagenetix compound.

Bill Spencer, CEO of Imagenetix, said: "The timing is perfect for us to establish a Scientific and Medical Advisory Board. We already have three studies published on Celadrin(R) in peer-reviewed journals, and we intend to conduct studies on our other products including Genepril, our patent-pending pharmaceutical discovery. Our belief is that talented medical and nutritional leaders can challenge us, provide insight, and assist us in the development of quality, innovative and remarkable products. It is my pleasure today to announce the acceptance to our Advisory Board of the three following members."

Accepting seats on the Imagenetix Scientific and Medical Advisory Board are:

Dr. Jonathan (Rick) Adachi, MD, FRCP(C), a professor within the Department of Medicine at McMaster University in Ontario, Canada, and a practicing rheumatologist at St. Joseph's Hospital in Hamilton, Canada. Dr. Adachi has conducted numerous clinical trials and has been published on a wide variety of medical therapies. Dr. Adachi's current focus is in the field of osteoarthritis where he has helped to develop a quality of life instrument for those with osteoporosis. Dr. Adachi is a member of the Osteoporosis Society of Canada and the International Osteoporosis Foundation.

Dan Gallaher, Ph.D., a professor and Associate Dean of Undergraduate programs in the College of Human Ecology, at the University of Minnesota. Dr. Gallaher is widely published in peer reviewed journals, and in symposia proceedings. His research interests include dietary influences on colon cancer and cholesterol metabolism, dietary fiber, dietary fat, bile acid metabolism, and dietary treatment of diabetes and chronic pancreatitis. Dr. Gallaher received his Ph.D. in Nutrition Science from the University of California, Davis. Dr. Gallaher is a member of numerous professional associations including the American Society of Nutritional Sciences, Society for Experimental Biology and Medicine, and the American Association for the Advancement of Science.

Robert L. Beeten, who served as the United States Olympic Committee's (USOC's) medical director from 1976 through 2000, and acted as the head athletic trainer and medical coordinator during six different Olympics from 1968 to 1984. From 1994 to 2000, Mr. Beeten held the title of the Director of Sports Medicine for the United States Olympic Committee.

About Celadrin(R)

Celadrin(R), a natural compound composed of esterified fatty acid carbons (EFACs) and other active synergists, is a proprietary Imagenetix product. Celadrin(R) can be formulated into both pill and cream forms and it can be used in formulations with other compounds to address the $22 billion joint health market.

In a double-blind, multi-center, placebo-controlled clinical trial of Celadrin(R), researchers examined the impact of an oral administration of Celadrin(R) on participants who were experiencing joint and mobility challenges of the knee. The placebo group and the Celadrin(R) group were evaluated at baseline, at 30 days, and at 68 days. Data from the study indicated that Celadrin(R) not only promoted joint flexibility, but also supported and promoted the ability to walk long distances.(a)

In an age-matched, double-blind study of patients diagnosed with osteoarthritis of the knee, researchers examined the impact of a topical administration of Celadrin(R) on participants. The placebo group and the Celadrin(R) group were evaluated at baseline, 30 minutes following initial treatment, and after 30 days, having applied the cream twice per day. Study data revealed that 100% of the participants using the Celadrin(R) cream experienced significant improvement in their ability to ascend and descend stairs, exhibit greater range of motion of the knee, ease of rising from a chair, functional mobility, and improved quality of life.(a) A most unique finding was that participants using the Celadrin(R) cream experienced an immediate effect from the treatment 30 minutes following the initial application.

(a) These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About Imagenetix, Inc.

San Diego-based Imagenetix, Inc. (OTCBB:IAGX), www.imagenetix.net, is an innovator of scientifically tested, natural-based, proprietary bioceutical products that enhance human and animal health. The Company develops, formulates and private-labels proprietary, leading-edge over-the-counter topical creams, skin care products and nutritional supplements to be marketed globally through multiple channels of distribution. Imagenetix also develops and formulates proprietary patentable pharmaceutical products.

Safe Harbor Statement

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.